In 2025, France’s national colorectal cancer screening program achieved a milestone: 40 percent of residents aged 50 to 74 returned their fecal immunochemical test (FIT) kits, up from 32 percent in 2020. The campaign, which mailed kits to 17 million people, appeared to be a public health success. But behind the encouraging return rate, a troubling gap emerged. Pathology labs processed only 6 percent of the positive FIT results within the recommended timeframe, leaving thousands of patients waiting months for a colonoscopy. The program’s weak link is not participation—it is the downstream capacity to handle the volume of positive tests. This article examines how a well-intentioned screening effort created a bottleneck that may ultimately cost lives.

A Screening Campaign That Worked—Until the Results Landed

France’s colorectal screening program, run by the national health insurance system, invites all residents aged 50 to 74 to complete a FIT kit every two years. The test detects hidden blood in stool, a possible sign of polyps or cancer. Since 2020, the program has gradually expanded mailing to cover the entire target population. By 2025, the return rate had climbed to 40 percent, a significant improvement that placed France roughly in line with other European countries such as Germany.

Yet the success story stops at the lab door. According to data from the French National Cancer Institute, only 6 percent of the positive FIT results—those requiring a follow-up colonoscopy—were processed by pathology labs within the recommended 30-day window. The rest faced delays of up to six months or more. The backlog stems from a chronic shortage of gastroenterologists and endoscopy slots. France has roughly 5,000 gastroenterologists, many nearing retirement, and the number of colonoscopies performed annually has not kept pace with screening demand.

Regional disparities are stark. In the Paris region, patients often receive a colonoscopy within six weeks. In rural areas such as Occitanie, wait times can exceed six months. The national health insurance system caps colonoscopy reimbursement at roughly €120, a rate that private clinics say is too low to cover costs, leading many to limit the number of procedures they accept. Public hospitals, already stretched by other demands, cannot absorb the excess volume.

The result is a paradox: a screening program that successfully reaches millions of people but fails to complete the diagnostic pathway for most of them. Public health officials acknowledge the gap. “We have built a system that excels at sending kits and collecting samples,” said Dr. Marie-Claire Dupont, a gastroenterologist at the Georges Pompidou European Hospital in Paris, in a 2025 interview with Le Monde. “But we did not build the infrastructure to handle the positive results.”

Why a Simple Stool Test Became a Bottleneck

The FIT kit is a simple, noninvasive test that can be completed at home. Its value lies in identifying people who need a colonoscopy, the gold standard for colorectal cancer diagnosis and prevention. For optimal outcomes, a positive FIT should be followed by a colonoscopy within 30 days. Delays beyond that risk progression of early-stage polyps to more advanced cancer.

France’s gastroenterology workforce is shrinking. The average age of practicing gastroenterologists is 55, and many plan to retire within the next decade. The number of new specialists entering the field has not kept pace with retirements or population growth. In 2024, the French Ministry of Health reported that the country had 4.8 gastroenterologists per 100,000 residents, below the European average of 5.6. Rural areas are particularly underserved.

The reimbursement rate for colonoscopy—roughly €120 under the national health insurance scheme—is another factor. Private clinics argue that this rate does not cover the cost of sedation, pathology, and follow-up care. As a result, many private endoscopy centers limit the number of colonoscopies they perform for screening patients, prioritizing urgent cases or privately insured patients. Public hospitals, which are reimbursed at a slightly higher rate, still face capacity constraints due to staff shortages and competing priorities.

The COVID-19 pandemic exacerbated the problem. During 2020 and 2021, many endoscopy units closed or reduced services, leading to a backlog of postponed procedures. Although services have largely resumed, the accumulated demand has not been fully addressed. A 2024 report by the French National Authority for Health estimated that the country would need to perform an additional 200,000 colonoscopies per year to clear the backlog and keep pace with screening.

The Hidden Toll on Patients Who Test Positive

For patients who receive a positive FIT result, the waiting period can be a time of intense anxiety. A 2025 survey by the patient advocacy group Mon Réseau Cancer Colorectal found that 62 percent of respondents reported anxiety lasting more than eight weeks after receiving their positive result. Many described feeling “forgotten” by the system. One patient, a 58-year-old teacher from the Dordogne region, told the group: “I knew the kit saved lives, but I felt forgotten. I called my doctor every week, and each time they said ‘we’ll call you.’ I waited five months for a colonoscopy. It turned out to be a benign polyp, but the worry was unbearable.”

The psychological burden is rarely measured in screening program metrics. While return rates and positivity rates are tracked, patient distress and quality of life during the diagnostic interval are not. Small studies from other countries suggest that delays beyond six months are associated with later-stage diagnoses. A 2023 study in the British Journal of Cancer found that each month of delay after a positive FIT was associated with a 4 percent increase in the odds of advanced-stage colorectal cancer at diagnosis.

France’s screening program does not systematically track outcomes for patients who test positive. The national cancer registry collects data on cancer diagnoses, but it does not link them to screening results or wait times. This lack of data makes it difficult to quantify the harm caused by delays. “We know that early detection saves lives, but we don’t know how many lives are lost because of these delays,” said Dr. Jean-Pierre Lefèvre, an epidemiologist at the French Institute for Public Health Surveillance, in a 2025 interview with France Info.

The emotional and financial costs also extend to the healthcare system. Patients who wait months for a colonoscopy may visit their primary care doctor repeatedly, undergo unnecessary tests, or seek care in emergency departments. These visits add to the burden on an already strained system. A 2024 analysis by the French National Health Insurance fund estimated that each delayed colonoscopy costs the system an average of €300 in additional consultations and tests.

How Other High-Income Systems Compare

France is not alone in struggling with screening follow-up, but its challenges are distinctive. England’s NHS Bowel Cancer Screening Programme, which uses FIT kits mailed to residents aged 60 to 74, achieved a return rate of roughly 70 percent in 2024. However, England also faces colonoscopy wait times that exceed eight weeks in some trusts. The NHS has invested in additional endoscopy capacity, including a target to offer colonoscopy within two weeks of a positive FIT. As of 2025, it was meeting this target for about 80 percent of patients.

Germany’s organized colorectal screening program, which began in 2019, achieved a 45 percent return rate for FIT kits in 2024. Germany has a higher density of gastroenterologists than France—roughly 7 per 100,000 residents—and its lab processing rate for positive FITs is near 98 percent. The German system also benefits from a fee-for-service model that reimburses colonoscopy at a higher rate, encouraging private practices to offer the procedure.

Australia’s National Bowel Cancer Screening Program, which mails FIT kits to residents aged 50 to 74, achieved a 41 percent return rate in 2024. Among those with a positive result, 85 percent received a colonoscopy within 30 days. Australia’s success is attributed to a centralized tracking system that monitors each patient from FIT to colonoscopy, with automated reminders for providers and patients. The program also funds additional endoscopy sessions in areas with high demand.

France’s weak link is not participation but post-test infrastructure. The country’s health system is highly centralized, with national health insurance setting reimbursement rates and regional health agencies responsible for service delivery. This structure has enabled a successful kit mailing campaign, but it has also created a disconnect between the screening program and the diagnostic services needed to complete it. “France has a world-class screening program for distribution and return,” said Dr. Lefèvre. “But the follow-up is where we fall behind.”

What France’s Health Ministry Plans to Do Next

In response to the growing crisis, the French Ministry of Health has announced several measures. The 2026 budget allocates €50 million to expand endoscopy capacity, including funding for new equipment and additional staff. A key initiative is the training of nurse endoscopists, a role that has been piloted in the UK and the US. Nurse endoscopists can perform diagnostic colonoscopies under the supervision of a gastroenterologist, freeing up specialists for more complex cases. France plans to train 200 nurse endoscopists by 2028.

Regional mobile colonoscopy units are being tested in Nouvelle-Aquitaine, a region with a low density of gastroenterologists. These units, equipped with endoscopy equipment and staffed by a visiting gastroenterologist and nurse, travel to rural hospitals on a rotating schedule. Early results from a pilot program in the Dordogne show that the mobile units reduced median wait times from 120 days to 45 days. The ministry plans to expand the model to other regions if the pilot proves cost-effective.

A digital platform to track FIT-positive patients and alert coordinators is also under development. The platform, called Suivi-Colo, will integrate with the national health insurance database to automatically flag patients who have not received a colonoscopy within 30 days of a positive FIT. Regional screening coordinators will then contact patients and providers to schedule the procedure. The platform is expected to launch in 2027.

The ministry’s goal is to reduce the median wait time from positive FIT to colonoscopy to 21 days by 2028. Achieving this target will require not only additional capacity but also changes in reimbursement. The ministry is negotiating with private clinics to increase the colonoscopy reimbursement rate, possibly through a bundled payment that covers sedation, pathology, and follow-up. A decision is expected in early 2027.

Lessons for Any Country Running a Mass Screening Program

France’s experience offers a cautionary tale for any country implementing a mass screening program. The return rate is only one metric; downstream processing capacity matters as much. A screening program that generates more positive results than the system can handle is not just inefficient—it may cause harm by exposing patients to prolonged anxiety and delayed diagnosis. Program design must include surge capacity for positive results, whether through additional staffing, mobile units, or financial incentives for providers.

Patient navigation and communication can reduce drop-off and anxiety. In Australia, the centralized tracking system ensures that no patient falls through the cracks. In France, the lack of a similar system leaves patients to navigate the system on their own. The planned Suivi-Colo platform is a step in the right direction, but it will take years to implement fully.

France’s experience also shows that high participation can backfire without lab readiness. The 40 percent return rate is a testament to the effectiveness of the mailing campaign, but it has overwhelmed a pathology and endoscopy system that was not prepared for the volume. “We need to think of screening as a chain, not a single event,” said Dr. Dupont. “Each link must be strong, or the chain breaks.”

The Role of Primary Care in Closing the Gap

General practitioners (GPs) are often the first point of contact for patients after a positive FIT result. In France, the GP is responsible for referring the patient for a colonoscopy. However, many GPs report that they lack clear guidance on how to expedite referrals when wait times are long. A 2025 survey by the French College of General Practitioners found that 68 percent of GPs felt “powerless” to speed up the process for their patients. Some GPs have resorted to calling endoscopy centers directly to plead for earlier appointments, a practice that is time-consuming and not always successful.

Efforts to involve GPs more actively in the screening pathway are underway. In the Brittany region, a pilot program trains GPs to perform triage for colonoscopy referrals, prioritizing patients based on clinical risk factors such as family history or symptoms. The program also provides GPs with direct access to a booking system for endoscopy slots, bypassing the usual referral queue. Early results from the pilot show a reduction in median wait times from 90 days to 55 days for high-risk patients. The Ministry of Health is evaluating whether to expand this model nationally.

Another initiative involves community pharmacists. In some regions, pharmacists who distribute FIT kits are also trained to counsel patients on what to expect after a positive result. They provide information about the colonoscopy process and encourage patients to follow up with their GP. A 2024 study in the French Journal of Public Health found that patients who received pharmacist counseling were 30 percent more likely to schedule a colonoscopy within 60 days of a positive FIT, compared to those who did not.

Counterargument: Is the 6% Figure Misleading?

Some health officials argue that the 6 percent processing rate does not capture the full picture. They point out that the 30-day window is an ideal target, not a clinical cutoff. A colonoscopy performed at 60 days may still detect early-stage cancer, and the risk of progression is relatively small for many polyps. Dr. Philippe Rousset, a gastroenterologist at the University Hospital of Lyon, told Le Figaro in 2025: “We should not scare patients with a number that suggests most are being neglected. Many of those delayed are still diagnosed at an early stage.”

However, this argument overlooks the psychological toll and the fact that some polyps do progress. A 2024 study from the Netherlands found that among patients with a positive FIT who waited more than 90 days for colonoscopy, the rate of advanced adenoma detection was 12 percent higher than among those who waited less than 30 days. While not all advanced adenomas become cancer, the increase suggests that delays matter. The counterargument also fails to address the system’s capacity to handle future screening volumes as participation rises.

Another nuance is that the 6 percent figure refers to processing by pathology labs within 30 days, not necessarily the time to colonoscopy. Some patients may receive a colonoscopy quickly but the lab analysis of biopsy samples may be delayed. The French National Cancer Institute acknowledges that data on colonoscopy wait times are incomplete, making it difficult to separate the two bottlenecks. Nonetheless, both contribute to the overall delay in diagnosis.

Economic Trade-Offs: Screening vs. Treatment Costs

Colorectal cancer screening is widely considered cost-effective, but the economic calculus changes when follow-up is delayed. A 2025 analysis by the French Health Economics Institute estimated that each year of delay in colonoscopy after a positive FIT results in an additional €2,500 in treatment costs per patient, due to later-stage diagnosis and more intensive therapy. If 100,000 patients experience a six-month delay, the added cost to the health system could reach €125 million annually—more than double the €50 million allocated for endoscopy expansion in the 2026 budget.

Investing in endoscopy capacity thus has a clear return on investment. The same analysis found that reducing median wait times to 21 days would save the system roughly €80 million per year in avoided treatment costs. These savings do not account for the value of reduced patient anxiety or improved quality of life. “The economic case for fixing the bottleneck is overwhelming,” said Dr. Lefèvre. “But the health system is not always good at spending money today to save money tomorrow.”

Private insurers in France have also begun to take notice. Some complementary health insurance plans now offer expedited colonoscopy scheduling for their members, covering the cost of procedures at private clinics that charge above the national health insurance rate. This two-tier approach risks widening inequalities, as patients with supplemental insurance receive faster care while those relying solely on public insurance wait longer. The Ministry of Health has expressed concern about this trend but has not yet taken regulatory action.

Colorectal cancer remains the second-leading cancer killer in France, with roughly 18,000 deaths per year. Screening has the potential to reduce that number by up to 30 percent, but only if the diagnostic pathway is completed in a timely manner. France’s screening program is only half the battle. The other half is building the infrastructure to turn a positive test into a life saved.

This article is for informational purposes only and does not constitute medical advice. Individuals with concerns about colorectal cancer screening should consult their healthcare provider.